22nd Century Group, Inc. filed a Form S-8 registration statement with the SEC on November 16, 2026, to register additional shares under its Amended and Restated 2021 Omnibus Incentive Plan following a 1-for-58 reverse stock split completed in November 2026.
MapLight Therapeutics, Inc. filed a Current Report on Form 8-K on November 16, 2026, announcing its financial results for the third quarter ended September 30, 2026, and an updated corporate presentation furnished under Regulation FD.
QVC Group, Inc. filed a quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission covering the fiscal quarter ended September 30, 2026, disclosing its financial position, results of operations, and material risk factors following its emergence from Chapter 11 bankruptcy proceedings.
The Macerich Company filed an 8-K with the SEC on November 16, 2026, disclosing its acquisition of Oakridge Mall in San Jose, California, for a purchase price of approximately $250 million.
Director Rafael De La Vega filed a Form 4 with the SEC on November 16, 2026, disclosing a purchase of Amdocs Ltd ordinary shares on November 12, 2026.
Xtant Medical Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, disclosing operational details, strategic developments, and a share count of 140,452,061 as of November 13, 2026.
Barrel Energy, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 16, 2026, reporting a net loss of $1,518,216 for the nine months ended September 30, 2026.
Prelude Therapeutics Incorporated filed its quarterly report on Form 10-Q with the SEC on November 16, 2026, covering the three and nine months ended September 30, 2026.
Instil Bio, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, disclosing a net loss of $4.231 million for the third quarter and $13.023 million for the nine months ended September 30, 2026.
Translational Development Acquisition Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 16, 2026, reporting a net loss of $9,293,622 for the third quarter and disclosing a new $10,200,000 Subscription Agreement liability on its balance …